Tag: Urothelial cancer
AstraZeneca receives marketing permission for Durvalumab (ImfinziTM) in India
Durvalumab is the only immunotherapy approved for patients with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) and was granted US FDA ‘breakthrough therapy’ designation on July 31, 2017.....................